Want to see CSTL full AI Analyst Report?
CSTL Stock Chart & Stats
$35.00
-$0.41(-1.68%)
At close: 4:00 PM EDT
$35.00
-$0.41(-1.68%)
Day’s Range― - ―
52-Week Range$17.72 - $44.28
Previous CloseN/A
Volume124.06K
Average Volume (3M)346.17K
Market Cap
$982.62M
Enterprise Value$494.86M
Total Cash (Recent Filing)$266.81M
Total Debt (Recent Filing)$36.65M
Price to Earnings (P/E)―
Beta0.56
Next Earnings
Nov 05, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding30,549,507
10 Day Avg. Volume344,759
30 Day Avg. Volume346,170
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.39
Price to Sales (P/S)3.28
P/FCF Ratio39.81
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue1.39
Enterprise Value/Gross Profit1.79
Enterprise Value/Ebitda-152.92
Forecast
1Y Price Target
$45.40Price Target Upside29.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$373.21M
Bulls Say, Bears Say
Bulls Say
Revenue And Volume GrowthStrong revenue and test-volume growth indicate expanding clinical adoption across Castle’s commercial portfolio. The raised annual guidance provides evidence that momentum is broad enough to support continued investment in commercial reach, laboratory capacity, and evidence generation over the next several quarters.
Portfolio Expansion And Clinical ValidationGrowth in TissueCypher and progress from AdvanceAD-Tx diversify the company beyond its established melanoma franchise. Prospective and real-world evidence can strengthen clinician adoption, support reimbursement discussions, and improve the durability of demand for multiple proprietary assays.
Cash Generation And Low LeverageA lightly levered balance sheet and positive free cash flow give Castle meaningful financial flexibility. Its cash and investment position can fund commercial expansion, clinical evidence, and laboratory capacity without relying heavily on debt, while limiting solvency pressure during execution.
Bears Say
Inconsistent GAAP ProfitabilityThe return to GAAP losses shows that revenue growth has not yet translated into stable earnings. Persistent losses can constrain internally funded investment, make operating performance more sensitive to volume and reimbursement changes, and weaken confidence in sustainable operating leverage.
Gross Margin CompressionLower gross margins reduce the amount of each test dollar available to cover sales, research, and corporate costs. Management’s expectation for continued low-to-mid-70s margins suggests the pressure may persist, limiting the earnings benefit of portfolio growth unless mix and cost trends improve.
Reimbursement Uncertainty For DecisionDx-SCCUncertain Medicare coverage creates a structural commercialization risk for DecisionDx-SCC because reimbursement directly affects physician adoption and realized revenue per test. A potentially lengthy recovery timeline could delay the assay’s contribution and require continued commercial investment before payment resumes.
Castle Biosciences News
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $17.72 and its highest was $44.28 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $982.62M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Jul 30, 2026. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.407 by $0.337.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -0.35.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 30,549,507 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.407. Following the earnings report the stock price went up 4.517%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.40 (29.71% Upside)
$45.40 (29.71% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 80%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 2.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.1%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.06%
12-Months-Change
Fundamentals
Return on Equity
-4.15%
Trailing 12-Months
Asset Growth
3.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Castle Biosciences
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
CSTL Company Deck
CSTL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents strong operational momentum: revenue and core test volumes grew materially (20% total revenue growth, 32% core volume growth), TissueCypher delivered robust 63% YoY growth and management raised full‑year guidance. The company is investing to scale commercial reach, evidence generation and lab capacity and reports positive adjusted EBITDA and a healthy cash position. Key challenges include margin compression, higher operating expenses that produced a small GAAP net loss in the quarter, uncertainty around Medicare coverage for SCC, and near‑term sales force tradeoffs affecting melanoma seasonality. On balance the positives (revenue/volume acceleration, guidance raise, evidence/regulatory progress, cash runway and adjusted EBITDA) outweigh the negatives.View all CSTL earnings summariesCSTL Stock 12 Month Forecast
Average Price Target
$45.40
▲(29.71% Upside)
Technical Analysis
Ownership Overview
1.97% Insiders
16.18% Mutual Funds
1.06% Other Institutional Investors
65.18% Public Companies and
Individual Investors